The Latest
-
Oil’s OPEC+ Boost Eases With Compliance Concerns Lingering
-
AstraZeneca-Gilead Deal to Face Political, Strategic Hurdles
-
Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick
-
These Analysts Think Auxly Cannabis Group Inc.’s (CVE:XLY) Sales Are Under Threat